# OnCo record paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022" ;
  schema:name "POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer"@en ;
  schema:description "The final results of POLO showed that olaparib did not lengthen overall survival on average, although about twice as many patients on olaparib were alive at three years, and the drug delayed the time until a second treatment was needed."@en ;
  schema:url <https://onco.cc/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.21.01604>, <https://pubmed.ncbi.nlm.nih.gov/35834777/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.21.01604> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Kindler HL, Hammel P, Reni M, et al." ;
  onco:cancers <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/> ;
  onco:trials <https://onco.cc/trials/polo/> ;
  onco:people <https://onco.cc/people/hedy-kindler/>, <https://onco.cc/people/talia-golan/> ;
  onco:journals <https://onco.cc/journals/jco/> .